Skip to main content
Premium Trial:

Request an Annual Quote

SEC Investigating Sequenom over Down Syndrome Test

NEW YORK (GenomeWeb News) – Sequenom disclosed in a filing with the US Securities and Exchange Commission Tuesday that the SEC is investigating the firm over its announcement in late April regarding the mishandling of R&D test data and results for its SEQureDx Down syndrome test.

The filing does not detail the SEC's concerns, but Sequenom said that it intends to "cooperate fully with the SEC in this matter." It added, "Our internal investigation is ongoing."

The firm had announced in late April that the mishandling of the test data meant that it would delay launch of the test until the third quarter of this year. The firm had previously expected to launch the test in June.

It also said that it had suspended four employees, put a new team in place to oversee studies of its prenatal diagnostics, and had convened an internal investigation.

The announcement led to the filing of several class action shareholder suits against Sequenom.

Earlier in June, shares of Sequenom jumped sharply on rumors that the firm may be close to finishing its internal investigation. However, the company has not indicated that such an announcement is imminent.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.